192 related articles for article (PubMed ID: 18073275)
1. Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of Delta9-tetrahydrocannabinol.
Buchweitz JP; Karmaus PW; Williams KJ; Harkema JR; Kaminski NE
J Leukoc Biol; 2008 Mar; 83(3):785-96. PubMed ID: 18073275
[TBL] [Abstract][Full Text] [Related]
2. Modulation of airway responses to influenza A/PR/8/34 by Delta9-tetrahydrocannabinol in C57BL/6 mice.
Buchweitz JP; Karmaus PW; Harkema JR; Williams KJ; Kaminski NE
J Pharmacol Exp Ther; 2007 Nov; 323(2):675-83. PubMed ID: 17726158
[TBL] [Abstract][Full Text] [Related]
3. Role of cannabinoid receptors in Delta-9-tetrahydrocannabinol suppression of IL-12p40 in mouse bone marrow-derived dendritic cells infected with Legionella pneumophila.
Lu T; Newton C; Perkins I; Friedman H; Klein TW
Eur J Pharmacol; 2006 Feb; 532(1-2):170-7. PubMed ID: 16443217
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of cannabinoids (CB) in a murine model of allergen-induced airway inflammation: role of CB1/CB2 receptors.
Braun A; Engel T; Aguilar-Pimentel JA; Zimmer A; Jakob T; Behrendt H; Mempel M
Immunobiology; 2011 Apr; 216(4):466-76. PubMed ID: 21056512
[TBL] [Abstract][Full Text] [Related]
5. Role of cannabinoid receptors in inhibiting macrophage costimulatory activity.
Chuchawankul S; Shima M; Buckley NE; Hartmann CB; McCoy KL
Int Immunopharmacol; 2004 Feb; 4(2):265-78. PubMed ID: 14996418
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
[TBL] [Abstract][Full Text] [Related]
8. Δ9-tetrahydrocannabinol impairs the inflammatory response to influenza infection: role of antigen-presenting cells and the cannabinoid receptors 1 and 2.
Karmaus PW; Chen W; Crawford R; Kaplan BL; Kaminski NE
Toxicol Sci; 2013 Feb; 131(2):419-33. PubMed ID: 23152191
[TBL] [Abstract][Full Text] [Related]
9. Role of cannabinoid receptors in alcoholic hepatic injury: steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts.
Trebicka J; Racz I; Siegmund SV; Cara E; Granzow M; Schierwagen R; Klein S; Wojtalla A; Hennenberg M; Huss S; Fischer HP; Heller J; Zimmer A; Sauerbruch T
Liver Int; 2011 Jul; 31(6):860-70. PubMed ID: 21645218
[TBL] [Abstract][Full Text] [Related]
10. Delta(9)-Tetrahydrocannabinol enhances MCF-7 cell proliferation via cannabinoid receptor-independent signaling.
Takeda S; Yamaori S; Motoya E; Matsunaga T; Kimura T; Yamamoto I; Watanabe K
Toxicology; 2008 Mar; 245(1-2):141-6. PubMed ID: 18249480
[TBL] [Abstract][Full Text] [Related]
11. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation.
Caffarel MM; Sarrió D; Palacios J; Guzmán M; Sánchez C
Cancer Res; 2006 Jul; 66(13):6615-21. PubMed ID: 16818634
[TBL] [Abstract][Full Text] [Related]
12. Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis.
Engel MA; Kellermann CA; Burnat G; Hahn EG; Rau T; Konturek PC
J Physiol Pharmacol; 2010 Feb; 61(1):89-97. PubMed ID: 20228420
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors.
Gaffal E; Cron M; Glodde N; Tüting T
Allergy; 2013 Aug; 68(8):994-1000. PubMed ID: 23889474
[TBL] [Abstract][Full Text] [Related]
14. Δ9-tetrahydrocannabinol suppresses cytotoxic T lymphocyte function independent of CB1 and CB 2, disrupting early activation events.
Karmaus PW; Chen W; Kaplan BL; Kaminski NE
J Neuroimmune Pharmacol; 2012 Dec; 7(4):843-55. PubMed ID: 21789506
[TBL] [Abstract][Full Text] [Related]
15. Time-dependent airway epithelial and inflammatory cell responses induced by influenza virus A/PR/8/34 in C57BL/6 mice.
Buchweitz JP; Harkema JR; Kaminski NE
Toxicol Pathol; 2007 Apr; 35(3):424-35. PubMed ID: 17487773
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation.
McCoy KL; Matveyeva M; Carlisle SJ; Cabral GA
J Pharmacol Exp Ther; 1999 Jun; 289(3):1620-5. PubMed ID: 10336560
[TBL] [Abstract][Full Text] [Related]
17. The inhibitory action of exo- and endocannabinoids on [³H]GABA release are mediated by both CB₁and CB₂receptors in the mouse hippocampus.
Andó RD; Bíró J; Csölle C; Ledent C; Sperlágh B
Neurochem Int; 2012 Jan; 60(2):145-52. PubMed ID: 22133429
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism.
Hayakawa K; Mishima K; Hazekawa M; Sano K; Irie K; Orito K; Egawa T; Kitamura Y; Uchida N; Nishimura R; Egashira N; Iwasaki K; Fujiwara M
Brain Res; 2008 Jan; 1188():157-64. PubMed ID: 18021759
[TBL] [Abstract][Full Text] [Related]
19. Structural modifications of the cannabinoid side chain towards C3-aryl and 1',1'-cycloalkyl-1'-cyano cannabinoids.
Papahatjis DP; Nahmias VR; Andreou T; Fan P; Makriyannis A
Bioorg Med Chem Lett; 2006 Mar; 16(6):1616-20. PubMed ID: 16387492
[TBL] [Abstract][Full Text] [Related]
20. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.
Steffens S; Veillard NR; Arnaud C; Pelli G; Burger F; Staub C; Karsak M; Zimmer A; Frossard JL; Mach F
Nature; 2005 Apr; 434(7034):782-6. PubMed ID: 15815632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
